title: Pharmacy-Driven Dexmedetomidine Stewardship and Appropriate Use Guidelines in a Community Hospital Setting.
abstract: BACKGROUND
  Dexmedetomidine is a widely utilized agent in the intensive care unit (ICU) because it does not suppress respiratory drive and may be associated with less delirium than midazolam or propofol. Cost of dexmedetomidine therapy and debate as to the proper duration of use has brought its use to the forefront of discussion.
  
  
  OBJECTIVE
  To validate the efficacy and cost savings associated with pharmacy-driven dexmedetomidine appropriate use guidelines and stewardship in mechanically ventilated patients.
  
  
  METHODS
  This was a retrospective cohort study of adult patients who received dexmedetomidine for ICU sedation while on mechanical ventilation at a 433-bed not-for-profit community hospital. Included patients were divided into pre-enactment (PRE) and postenactment (POST) of dexmedetomidine guideline groups.
  
  
  RESULTS
  A total of 100 patients (50 PRE and 50 POST) were included in the analysis. A significant difference in duration of mechanical ventilation (11.1 vs 6.2 days, P = 0.006) and incidence of reintubation (36% vs 18% of patients, P = 0.043) was seen in the POST group. Aggregate use of dexmedetomidine 200-µg vials (37.1 vs 18.4 vials, P = 0.010) and infusion days (5.4 vs 2.5 days, P = 0.006) were significantly lower in the POST group. Dexmedetomidine acquisition cost savings were calculated at $374 456.15 in the POST group. There was no difference between the PRE and POST groups with regard to ICU length of stay, expected mortality, and observed mortality.
  
  
  CONCLUSIONS
  Pharmacy-driven dexmedetomidine appropriate use guidelines decreased the use of dexmedetomidine and increased cost savings at a community hospital without adversely affecting clinical outcomes.
authors.affiliation: 1 KentuckyOne Health, Lexington, KY, USA.
authors.forename: M Alexandra
authors.initials: MA
authors.lastname: Schickli
authors.affiliation: 1 KentuckyOne Health, Lexington, KY, USA.
authors.forename: Kip A
authors.initials: KA
authors.lastname: Eberwein
authors.affiliation: 1 KentuckyOne Health, Lexington, KY, USA.
authors.forename: Marintha R
authors.initials: MR
authors.lastname: Short
authors.affiliation: 1 KentuckyOne Health, Lexington, KY, USA.
authors.forename: Patrick D
authors.initials: PD
authors.lastname: Ratliff
mesh_terms: D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D003693:Delirium / Q000139:chemically induced / Q000517:prevention & control; D020927:Dexmedetomidine / Q000008:administration & dosage* / Q000191:economics; D004363:Drug Utilization; D005260:Female; D006745:Hospital Bed Capacity, 300 to 499; D006764:Hospitals, Community; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage* / Q000191:economics; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D010607:Pharmacy Service, Hospital / Q000191:economics / Q000379:methods*; D000067561:Potentially Inappropriate Medication List; D017410:Practice Guidelines as Topic / Q000592:standards*; D012121:Respiration, Artificial; D012189:Retrospective Studies
chemical_list: D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine
keywords: clinical pharmacy; cost-containment; critical care; pulmonary; sedatives